Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | ODC1 | P11926 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980368 | 1.00 | HTR2C (0.41) | HTR2CHTR2BHTTNPSR1MEN1 | |
| SCHEMBL12748472 | 1.00 | HTR2C (0.41) | HTR2CHTR2BHTTNPSR1MEN1 | |
| SCHEMBL11098662 | 0.81 | HTR2C (0.44) | HTR2CHTR2BHTTNPSR1MEN1 | |
| SCHEMBL21257372 | 0.80 | PTGS1 (0.37) | MEN1MAPTKMT2ATSHRMAPK1 | |
| SCHEMBL6981088 | 0.78 | NPSR1 (0.43) | HTR2CNPSR1PTGS1PTGS2XDH | |
| SCHEMBL9208134 | 0.76 | HIF1A (0.43) | MAPTALDH1A1 | |
| SCHEMBL9206139 | 0.75 | CA12 (0.40) | KDM4EPTGS1PTGS2XDH | |
| SCHEMBL6980284 | 0.75 | CA12 (0.40) | KDM4EPTGS1PTGS2XDH | |
| SCHEMBL928563 | 0.74 | CA9 (0.44) | HTTMEN1MAPTKMT2ATSHR | |
| SCHEMBL9205782 | 0.74 | CA9 (0.44) | HTTMEN1MAPTKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070310-A1 | TOPICAL OPHTHALMIC PHARMACEUTICAL FORMULATION OF (2S,3S,4R)-N''-CYANO-N-(6-AMINO-3,4-DIHYDRO-3-HYDROXY-2-METHYL-2-DIMETHOXYMETHYL-2H-BENZOPYRAN-4-YL)-N'-BENZYLGUANIDINE | MESH THERAPEUTICS, LLC (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110020453-A1 | Topical Formulations Comprising Ion Channel Modulators | MESH THERAPEUTICS, LLC | 2011-01-27 | — | — | US | disclosed |
| EP-1330454-B1 | BENZOPYRANYL HETEROCYCLE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HITEK CO LTD (KR) | 2010-05-19 | — | — | EP | disclosed |
| EP-1228058-B1 | BENZOPYRANYL GUANIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2003-12-10 | — | — | EP | disclosed |
| EP-1228058-A4 | BENZOPYRANYL GUANIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2003-02-12 | — | — | EP | disclosed |
| EP-1228058-A1 | BENZOPYRANYL GUANIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dongbu Hannong Chemical Co., Ltd. (KR) | 2002-08-07 | — | — | EP | disclosed |
| US-6323238-B1 | CARDIOVASCULAR DISORDERS, NERVOUS SYSTEM DISORDERS | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2001-11-27 | — | — | US | disclosed |
| WO-2001029023-A1 | BENZOPYRANYL GUANIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020453-A1 | Topical Formulations Comprising Ion Channel Modulators | CACNA1E, CACNA1D, TRPV1 | HTR2C 2162/4885HTR2B 1214/4885HTT 2882/4885 |
| US-20110070310-A1 | TOPICAL OPHTHALMIC PHARMACEUTICAL FORMULATION OF (2S,3S,4R)-N''-CYANO-N-(6-AMINO-3,4-DIHYDRO-3-HYDROXY-2-METHYL-2-DIMETHOXYMETHYL-2H-BENZOPYRAN-4-YL)-N'-BENZYLGUANIDINE | QDPR, ACMSD, BPGM | HTR2C 999/4885HTR2B 544/4885HTT 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.